Polly Matzinger - Publications

Publications

• Matzinger, P. and Mirkwood, G. (1978). In a fully H-2 incompatible chimera, T cells of donor origin can respond to minor histocompatibility antigens in association with either donor or host H-2 type. Journal of Experimental Medicine, 148, 84-92.
• Lassila, O., Vainio, O. and Matzinger, P. (1988). Can B cells turn on virgin T cells? Nature, 334, 253-255. (the article in which "professional antigen presenting cells" were first named)
• Fuchs, E., and Matzinger, P. B. (1992). B cells turn off virgin but not memory T cells. Science, 258, 1156-1159.
• Matzinger, P. (1994). Tolerance, Danger, and the Extended Family. Ann. Reviews of Immunology, 12, 991-1045.
• Epstein, M. M., DiRosa, F., Jankovic, D., Sher, A., and Matzinger, P. (1995). Successful T cell priming in B cell deficient mice. Journal of Experimental Medicine, 182, 915-922.
• Di Rosa, F. and Matzinger, P. (1996). Long lasting CD8 T cell memory in the absence of CD4 T cells or B cells. Journal of Experimental Medicine, 183, 2153-2163.
• Ridge, J.P., Fuchs, E., and Matzinger, P. (1996). Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science, 271, 1723-1726.
• Ridge, J.P., Di Rosa, F. and Matzinger, P. (1998). A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T- killer cell. Nature, 393, 474-478.
• Gallucci, S., Lolkema, M. and Matzinger, P. (1999). Natural adjuvants: Endogenous activators of dendritic cells. Nature Medicine, 5, 1249-1255.
• Matzinger P. (2002). The Danger Model: A Renewed Sense of Self. Science, 296, 301-305.
• Seong, S. and Matzinger, P. (2004). Hydrophobicity, an ancient Damage-associated Molecular Pattern that initiates Innate Immune Responses. Nature Rev. Imm., 4, 469-78.
• Matzinger, P. (2007). Friendly and dangerous signals: is the tissue in control? Nature Immunol,8,11-13.
• Ainhoa Perez-Diez, Nathalie T. Joncker, Kyungho Choi, William F. N. Chan, Colin C. Anderson, Olivier Lantz, and Polly Matzinger. (2007). CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood, 109, 5346-5354.5346]